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intRoDUCtion anD HistoRiCal 
BaCKGRoUnD
Augmenting the immunogenicity of cancer cells to improve the 
efficacy of cancer therapy is a paradigm that has gained significant 
momentum over the past 5 years (1–5). Researchers have realized 
that besides therapeutically exploiting innate or adaptive immune 
cells directly (e.g., through dendritic cell (DC)-based vaccines or 
adoptive T-cell transfer) and/or improving the effector functions 
of T cells (through checkpoint-blocking therapies), cancer cells 
also need to be made immunogenic (1, 4, 6, 7). This has diverted 
attention toward studying the interface between stressed or dying 
cancer cells and the immune system, in the hope of efficiently 
exploiting it for therapeutic purposes (1).
Early indications regarding immune system-driven tumor 
control emerged in the eighteenth century, when feverish 
infections in cancer patients were circumstantially associated with 
tumor remission (8). The first evidence that immunotherapy can 
be applied to achieve tumor regression emerged from the work 
of William Coley, who in the 1890s achieved tumor regression 
in some sarcoma/lymphoma patients upon the intra-tumoral 
injection of streptococcal cultures (provided by Robert Koch) (8, 
9). In the following 43 years, Coley injected nearly 900 (mostly 
sarcoma) patients with his bacterial preparation (achieving a 
cure rate >10%), which later became known as “Coley’s toxin” 
(8, 10). However, the Coley’s toxin came under intense scrutiny 
owing to an elevated toxicity and some difficulties in reproducing 
remission rates (8). Eventually, the first experimental evidence 
that virus-unrelated tumors can indeed be recognized by the host 
immune system emerged in the 1940s, and by the 1960s, coupled 
with the discovery of T cells, it was proposed that the human 
immune system may also react against tumors (11). The ability 
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The immunogenicity of malignant cells has recently been acknowledged as a critical
determinant of efficacy in cancer therapy. Thus, besides developing direct immuno-
stimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking
therapies, and adoptive T-cell transfer, researchers have started to focus on the overall 
immunobiology of neoplastic cells. It is now clear that cancer cells can succumb to
some anticancer therapies by undergoing a peculiar form of cell death that is charac-
terized by an increased immunogenic potential, owing to the emission of the so-called 
“damage-associated molecular patterns” (DAMPs). The emission of DAMPs and other 
immunostimulatory factors by cells succumbing to immunogenic cell death (ICD) favors 
the establishment of a productive interface with the immune system. This results in
the elicitation of tumor-targeting immune responses associated with the elimination of
residual, treatment-resistant cancer cells, as well as with the establishment of immuno-
logical memory. Although ICD has been characterized with increased precision since its 
discovery, several questions remain to be addressed. Here, we summarize and tabulate 
the main molecular, immunological, preclinical, and clinical aspects of ICD, in an attempt 
to capture the essence of this phenomenon, and identify future challenges for this rapidly 
expanding field of investigation.
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of anticancer therapies to enhance the immunogenic potential of 
malignant cells gained some appreciation by the 1970s (12–14). 
It was recognized that if specific treatments are applied (e.g., 
radiotherapy, the bacillus Calmette–Guerin, or some chemo-
therapeutics), the immunogenicity of malignant cells increases 
enough to induce durable anti-tumor immunity (12–14). By the 
1980s, researchers started to report more specific observations 
regarding the therapeutic impact of cancer cell immunogenicity, 
e.g., the ability of curative hyperthermia to cause the (heat-shock 
based) generation of circumstantial anti-tumor immunity (15), 
the fact that the immunogenicity of cancer cells influences patient 
prognosis after radiotherapy (16), and the increase in tumor 
immunogenicity due to hydrostatic pressure (17). However, 
these early studies (especially those published before the 1980s) 
had several issues linked to a lack in consensus. For instance, 
due to early controversies on the existence of tumor-associated 
antigens (TAAs) (11), the target of tumor-specific immune 
responses was unclear, and the mechanism of action of some 
therapies came under scrutiny. Moreover, such therapies could 
operate by directly modulating immune effector cells rather 
than improving the immunogenic potential of tumors (18). In 
particular, the death of cancer cells exposed to therapy was never 
suspected to drive anti-tumor immunity, since it was considered 
to be a relatively “silent” process in terms of immunogenicity 
(19). Moreover, the classical “self/non-self ” theory was unable 
to explain the possibility that dying cancer cells could elicit an 
immune response (20).
By the early 1990s, the molecular characterization of mice 
and human TAAs clarified the entities targeted by anti-tumor 
immune responses (11). Similarly, the so-called “danger theory” 
started to emerge, challenging the classical model of “self/non-
self ” immune recognition, especially in a diseased or damaged 
tissue (20, 21). This model proposed that the immune recognition 
is not restricted to “non-self ” entities, but rather discriminates 
between “dangerous” and “safe” entities, irrespective of source 
(20–22). Indeed, “dangerous” entities include pathogens as well 
as injured, infected, diseased and necrotic tissues, or cells under-
going non-physiological cell death which emit danger signals (or 
alarmins) with pro-inflammatory activity (21, 22). These danger 
signals are now collectively referred to as “damage-associated 
molecular patterns” (DAMPs) (23). DAMPs are endogenous 
molecules that are concealed intracellularly in normal condi-
tions, but are exposed or released upon stress, injury, cell death, 
thereby becoming able to bind cognate receptors on immune 
cells (3, 24–27). Table 1 summarizes the most prominent DAMPs 
characterized to date and their mode of emission, the cell death 
pathway they are associated with, and their known cognate 
receptors. It is important to consider that not all DAMPs may 
act as immunogenic danger signals. Several DAMPs exist that 
are crucial for the maintenance of tissue homeostasis, and the 
avoidance of auto-immune responses, as they exert immunosup-
pressive effects, including phosphatidylserine (PS), annexin A1 
(ANXA1), death domain 1α (DD1α), B-cell CLL/lymphoma 
2 (BCL2) and some extracellular matrix-derived molecules 
(Table 1). Accordingly, the blockade of these anti-inflammatory 
DAMPs accentuates the immunogenic potential of dying cells, or 
renders immunogenic otherwise tolerogenic forms of cell death 
(28, 29). Moreover, some danger signals are not always involved 
in the immunogenicity of cell death, but act as “bystanders.” This 
is the case for heat shock protein 90 kDa alpha (cytosolic), class 
A member 1 (HSP90AA1, best known as HSP90) exposed on 
the cell surface after melphalan treatment (30). Last (but not 
least), several DAMPs may be subjected to post-translational 
modifications (e.g., oxidation, reduction, citrullination) that 
may potentially neutralize, increase, or change their immuno-
genic properties (31, 32)  –  a process that is still incompletely 
understood.
Despite these advances, the overall role of regulated cell death 
(RCD) (97) in augmenting cancer immunogenicity remained 
obscure. Initial observations involving the immunogenicity of 
cell death in the efficacy of cancer therapy were published between 
1998 and 2004, when it was proposed that the non-apoptotic 
demise of malignant cells (within the context of the so-called 
“immunogenic death”) could be associated with the emission 
of the danger signal heat shock 70 kDa protein 1A (HSPA1A, 
best known as HSP70) (Table 1), enhancing the immunogenic 
potential of dying cancer cells in  vivo (98, 99). The dogmatic 
view that only necrotic or non-apoptotic (as postulated by the 
“immunogenic death” concept) cancer cells are characterized by 
an elevated immunogenic potential started to be questioned by a 
series of studies published between 2005 and 2007 (41, 70, 100, 
101). These publications outlined that cancer cells undergoing 
apoptosis in response to specific anticancer therapies are immu-
nogenic [a subroutine termed immunogenic cell death (ICD)], as 
long as they emit precise DAMPs in a spatiotemporally defined 
fashion (26, 102, 103). Cells succumbing to ICD are sufficient 
for the elicitation of durable anti-tumor immune responses (1, 
26, 53, 102, 104). ICD is indeed paralleled by the redirection and 
emission of DAMPs, owing to the stimulation of distinct danger 
signaling pathways occurring in synchrony with cell death 
signaling (103). Table 2 summarizes the main signaling path-
ways that play a role in the trafficking and emission of DAMPs. 
ICD-associated DAMPs and other immunostimulatory factors 
released by cells destined to undergo ICD favor the establish-
ment of a productive interface between dying cancer cells and 
innate immune cells (like DCs or macrophages), thereby leading 
to the initiation of a therapeutically relevant adaptive immune 
response (Figure 1) (102, 105). In some contexts, DAMPs may 
regulate the function of specific innate immune cell subsets, 
e.g., following anthracycline treatment, extracellular adenosine 
triphosphate (ATP) assists in recruitment and differentiation of 
CD11c+Cd11b+Ly6Chigh cells into CD11c+CD86+MHCII+ DCs 
(106); similarly, necrosis associated F-actin exposure activates an 
immune response by directing the dead cell debris to specifically 
CD8α+ DCs (59, 107). Indeed, DCs and other antigen-presenting 
cells exposed to cancer cells succumbing to ICD can then prime 
CD4+ T cells (and polarize them into TH1, TH17, or TH1/TH17-
like phenotype), CD8+ cytotoxic T lymphocytes (CTLs) and γδ 
T lymphocytes against one or several TAAs (Figure 1) (102). Of 
note, residual cancer cells that survive ICD inducers can also 
show some enduring immunogenic characteristics that make 
them susceptible to immunological control by CTLs (108–110).
fiGURE 1 | the molecular complexity of immunogenic cell death in cancer. Cancer cells undergoing immunogenic cell death (ICD) emit danger signals for 
establishing a productive interface with components of the host immune system, including dendritic cells (DCs). DCs exposed to cancer cells succumbing to ICD 
“prime” the adaptive arm of the immune system, consisting of various effector T-cell populations, which in turn targets therapy-resistant cancer cells. Various 
molecules are critical for the execution of these processes. The molecular network of ICD-relevant proteins was build using the STRING modeling database (http://
string-db.org/) (126).
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iMMUnoGEniC CEll DEatH inDUCERs
Over the past few years, a number of single-agent ICD inducers 
have been discovered, encompassing conventional chemothera-
peutics, targeted anticancer agents and various other  biological 
and physicochemical therapies (18, 102, 104, 127). Table 3 sum-
marizes single-agent ICD inducers characterized so far, as per 
consensus guidelines (104), and the spectra of DAMPs and other 
immunostimulatory signals associated with them. For combina-
torial therapeutic strategies capable of achieving ICD, readers may 
want to refer to other recent publications (18, 128, 129). It is clear 
that a general structure–function relationship capable of cluster-
ing all existing ICD inducers and predicting new ones does not 
exist (130), an issue that makes discovering new ICD-inducing 
therapies based on cheminformatic analyses challenging, if not 
impossible. A peculiar characteristic of most, if not all, ICD induc-
ers is their ability to induce reactive oxygen species (ROS)-based/
associated endoplasmic reticulum (ER) stress, as first delineated 
for anthracyclines (30, 34, 35, 42, 123, 131–133). This peculiarity 
was exploited for the targeted discovery of hypericin-based pho-
todynamic therapy (Hyp-PDT) – a therapeutic modality that can 
trigger ICD through the induction of ROS that target the ER (35, 
116, 134). Along with an ever more precise characterization of the 
links between ROS, ER stress, and ICD induction (135, 136), it 
became clear that the more “focused” ER stress is, the higher the 
probability of inducing ICD (3, 26, 53, 137). These observations 
paved way for a classification system based on how ICD inducers 
engage ER stress for cell death and danger signaling (3, 26, 53, 
138). Based on this classification, Type I ICD inducers are defined 
as anticancer agents that act on non-ER proteins for the induction 
of cell death, but promote collateral ER stress for danger signaling, 
thereby operating on multiple targets (3, 26, 53), while Type II 
ICD inducers are anticancer agents that target the ER for both 
cell death induction and danger signaling (3, 26, 53). Table  4 
summarizes the classification of current ICD inducers into Type 
I and Type II, and their cell death/danger signaling targets. Such 
a classification suggest that while Type I ICD inducers can be 
discovered through various approaches (e.g., DAMP-based drug 
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screening platforms) (130, 139), putative Type II ICD inducers 
can be characterized rapidly on the basis of their ability to selec-
tively or predominantly target the ER. Recent findings comforted 
the purpose and usefulness of this classification system, as two 
novel Type II ICD inducers [i.e., PtII N-heterocyclic carbene 
complex (140) and Newcastle disease virotherapy (NDV) (43)] 
were identified based on the notion that they induce predominant 
ROS-based ER stress (138). Nevertheless, as more ICD inducers 
and features are discovered, this classification system is expected 
to evolve or be substituted by a more refined one.
Since its discovery, a plethora of molecular and immunological 
components responsible for ICD have been discovered (Figure 1) 
(26, 102, 188). Table 5 summarizes the molecular and immuno-
logical determinants of ICD characterized so far, as well as the 
models of ICD in which they operate (in a positive, negative or 
dispensable manner). Anthracyclines and oxaliplatin are the most 
common ICD inducers employed in experimental settings, fol-
lowed by Hyp-PDT. According to current understanding, cancer 
cell-associated determinants of ICD can be subdivided into those 
that are common to all ICD inducers (i.e., “core” signaling com-
ponents), and those that operate in an ICD inducer-dependent 
manner (i.e., “private” signaling components) (26, 189). Thus, 
eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3, 
best known as PERK) and the ER-to-Golgi secretory machinery 
are considered “core” signaling components on the cancer cell 
side (26, 102). Similarly, from the immune system side, a general 
role for (IFNγ-producing) CD4+ and CD8+ T cells has been con-
firmed for most, if not all, ICD inducers (Table 5). Interestingly, 
some components that are required for ICD induction by some 
agents (like autophagy for anthracyclines and oxaliplatin) (190) 
might be either dispensable for ICD induction by other agents, 
e.g., autophagy for NDV (43) and phosphorylation of eukaryotic 
translation initiation factor 2α (eIF2α), caspase-8 (CASP8) activa-
tion or cytosolic Ca2+ levels for Hyp-PDT (35); or even negatively 
regulate ICD in some settings, e.g., autophagy in case of Hyp-PDT 
(34) (Table 5). Thus, it will be important to expand our molecular 
knowledge of ICD to as many experimental settings as possible.
iMMUnoGEniC CEll DEatH fRoM 
BEnCH to BEDsiDE
The relevance of ICD has been verified in a number of rodent 
models, with a variety of chemical and physicochemical ICD 
inducers (26, 102). Table  6 summarizes the most prominent 
mouse or rat models used so far for the characterization and study 
of ICD. For the moment, ICD has been mostly investigated in 
heterotopic syngeneic subcutaneous models (195). Within such 
models, inter-species differences (mouse versus rats), inter-strain 
differences (among BALB/c, C57BL/6, C3H and KMF mice), and 
inter-cell line differences, as well as differences in therapeutic 
setups (prophylactic versus curative) have been amply accounted 
for (Table 6). Nevertheless, there is predominance in the use of 
cancer cells derived from carcinogen-induced tumors and trans-
planted subcutaneously (Table 6). In very few cases, ICD has been 
characterized in either orthotopic (for NDV) or spontaneous (for 
anthracyclines) tumor murine models (Table 6). This has been 
questioned as a prominent Achilles’ heel of ICD research (195). 
While this criticism is valid, it has to be recognized that no rodent 
model is perfect at all immunological levels (196).
As a recent systematic review summarized (196), heterotopic 
murine models suffer from a number of caveats, including the 
inability to recapitulate the early interaction between transformed 
cells and the immune system and the incompatibility between 
the cancer type and the site-of-transplantation (196). Orthotopic 
murine models are useful as they overcome the cancer cell-tissue 
type incompatibility issue (196). While genetically engineered 
tumor murine models (GEMMs) overcome most of the issues 
mentioned above, they come with their own set of shortcomings, 
including a limited genetic mosaicism, a low tumor heterogene-
ity, a lack of well-defined immunogenic TAAs, the presence of 
unintended “passenger” genetic modifications, and a reduced 
mutational spectrum (196). Many of these parameters are 
critical for responses to immunotherapy/ICD. For instance, the 
lack of well-defined immunogenic TAAs was the reason why 
preliminary results obtained in spontaneously developing murine 
tumors disputed the very existence of TAAs (11). Similarly, a high 
mutational spectrum (which produces considerable amounts of 
neo-antigens) has been found to be mandatory for the clinical 
efficacy of checkpoint blockers (209). Last (but not least), labora-
tory rodent models in general are associated with some critical 
issues, including the fact that a high level of inbreeding (which 
produces a number of shortcomings e.g., homozygous recessive 
defects) reduces the general immunological fitness, responsive-
ness and diversity in these models (196, 210, 211). Moreover, 
numerous immunological differences between mouse and 
humans tend to affect the translational relevance of the findings 
obtained (26, 211, 212). Also, the time frames of tumor growth 
rates between rodent models and humans are relatively divergent 
(196, 213, 214). This further complicates clinical translation of 
immunotherapeutic paradigms since the level of immunosurveil-
lance and immunoediting experienced by human tumors can be 
much higher than any rodent tumor model.
In summary, it would be ideal to test ICD across as many 
different rodent models as possible, in order to determine the fea-
tures that can be exploited for therapeutic purposes in humans. 
Moreover, if ICD fails in a specific experimental model, active 
effort should be made to characterize the mechanisms behind 
such failure, since resistance phenotypes can have profound clini-
cal implications. This emerges from various studies summarized 
in Table  7. Indeed, several ICD resistance mechanisms exist 
operating at both the cancer cell and the immune system level, 
which have been characterized in different experimental models. 
Several of these resistance mechanisms have also been identified 
in cancer patients, thereby justifying further studies along these 
lines Table 7.
A considerable amounts of clinical findings support the rel-
evance of ICD or ICD-related signatures in (at least subsets of) 
cancer patients. As summarized in Table 8, various ICD-linked 
(specific) parameters have been associated with the prognosis 
of cancer patients treated with clinically relevant ICD inducers 
(like anthracyclines, oxaliplatin, paclitaxel, or radiotherapy). 
Moreover, it is becoming clear that ICD-related or ICD-derived 
(immunological) genetic signatures (e.g., a MX1-centered 
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metagene, a CXCR3-PRF1-CASP1-centered metagene, an 
ASAH1-centered metagene) can be positively associated with 
good prognosis in patients affected by various neoplasms, includ-
ing breast, lung, and ovarian malignancies (141, 188, 220). These 
observations indicate that ICD or ICD-relevant parameters may 
have prognostic or predictive relevance in at least a subset of 
cancer patients. It will be important to characterize new and more 
specific ICD-associated parameters linked to patient prognosis as 
well as biomarkers that may predict improved disease outcome 
in cancer patient treated with ICD inducers. Of note, consider-
ing the current clinical experience with immunotherapies 
(209, 221), the patients with an increased likelihood to benefit 
from ICD inducers are probably those that display pre-existing 
(baseline) immune reactivity against cancer cells (220, 222, 223). 
This may depend on the ability of ICD  to reboot and/or revive 
pre-existing TAA-directed immunity rather to prime de novo 
immune reactivity (5, 191, 224). In future, it would be crucial to 
characterize biomarkers that allow clinicians to delineate patients 
with reduced baseline immune reactivity against malignant cells 
so that proper combinatorial therapies involving ICD inducers 
can be implemented.
ConfRontinG tHE CliniCal REalitiEs 
of anti-tUMoR iMMUnitY
It is well-established that the response of cancer patients to immu-
notherapy relies on the activity of effector T cells [that employ 
their T-cell receptors (TCRs) for recognizing TAAs]. However, 
these TAA-targeting T cells may also constitute obstacles for effec-
tive anti-tumor immunity (234). As opposed to T lymphocytes 
recognizing pathogen-associated antigens (PAAs) (Figure  2), 
indeed, T cells directed against some TAAs (derived from non-
mutated proteins that are source of self or near-to-self antigens) 
are developmentally subjected to negative selection in the thymus 
and peripheral lymphoid organs (234, 235) (Figure 2). As a result, 
T cells bearing TCRs with high affinity for self antigens (includ-
ing some TAAs) are clonally deleted to avoid auto-immunity 
(234–237) (Figure 2). However, some “leakiness” in this process 
allows TAA-specific T cells possessing TCRs with low affinity to 
escape deletion (234, 236, 237) and persist, although at low pre-
cursor frequencies (238) (Figure 2). Unfortunately, as compared 
to PAA-specific T cells, which bear high-affinity TCRs (Figure 2), 
TAA-specific T cells exhibit limited effector and memory func-
tions (234, 239). Coupled with the tendency of progressing tumors 
to generate a highly immunosuppressive microenvironment, this 
renders the insurgence of lifelong protective immunity nearly 
impossible (234). Of note, central and peripheral tolerance may 
not affect T cells reactive toward neo-tumor-specific antigens 
(neo-TSAs) e.g., tumor-specific neo-antigens that are generated 
de novo in the course of tumor progression because of mutational 
events (240, 241). However, the extent to which such neo-TSAs 
can elicit consistent “immunodominant” T cell reactivity is still a 
matter of investigation (240, 241). Nevertheless, in this context, 
inefficient T-cell stimulation can be overcome through the ICD-
based improvement of effector T-cell functions (102). ICD can 
be further combined with checkpoint-blocking therapies, which 
fiGURE 2 | Population dynamics of antigen-specific t cells during an 
immune response to infection or cancer. (a) T cells capable of putatively 
recognizing non-self, pathogen-associated antigens (PAAs) are not exposed 
to negative selection in the thymus or peripheral organs like lymph nodes. 
This allows for the constitutive presence of T lymphocytes bearing 
high-affinity T-cell receptor (TCR) in naïve conditions. Upon infection, these 
cells undergo robust expansion and acquire potent effector functions, hence 
driving an immune response that clears the pathogen and PAAs. Finally, 
PAA-specific T cells undergo contraction along with the establishment of 
immunological memory. To a limited extent, T cells reacting against PAAs 
expressed by virus-induced tumors may exhibit similar (although not identical) 
responses. (B) T cells that may recognize self or close-to-self antigens 
expressed by virus-unrelated malignancies undergo robust negative selection 
in the thymus and lymph nodes. Thus, all putative T lymphocytes bearing a 
high-affinity TCR against tumor-associated antigens (TAAs) are eliminated. 
However, some leakiness in this process allows for the persistence of 
TAA-specific T lymphocytes with low-affinity TCR, although at very low 
precursor frequencies. This is one of the reasons why in some individuals 
immunosurveillance at some stage fails to impede tumor progression. As 
malignant lesions progress, the amount of TAAs increases, causing a weak 
rise in TAA-specific T cells. However, tumor progression is generally coupled 
with the establishment of robust immunosuppressive networks that potently 
inhibit such TAA-targeting T cells. In this context, the administration of 
immunogenic cell death (ICD) according to a schedule that does not lead to 
lymphodepletion can favor the stimulation of TAA-targeting T cells and (re)
instate immunosurveillance. Combining ICD inducers with checkpoint-
blocking agents may further boost TAA-targeting immune responses. 
However, these treatments may not ensure the lifelong persistence of 
TAA-recognizing T cells, some of which are susceptible to elimination 
through tolerance mechanisms. Anticancer vaccines may counteract, at 
least to some extent, such loss. The figure was partly inspired from Baitsch 
et al. (234).
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potently reverse immunosuppression (209, 242). However, the 
lifelong maintenance of anti-tumor T cells remains a particularly 
hard challenge.
In the clinical reality, anticancer agents are administered to 
patients in a limited number of cycles. Even if these therapeutic 
regimens may attain optimal efficacy in terms of ICD induction, 
they are unlikely to ensure the lifelong persistence of TAA-
directed T cells with low-affinity TCR (234, 243). This probably 
reflects the contraction of TAA-targeting T cells occurring once 
the immunostimulatory stimulus provided by ICD ceases, owing 
to peripheral tolerance mechanisms (234). Clinically, it may not 
be feasible to administer ICD inducers repeatedly over time, 
since many of them can cause lymphopenia (which negatively 
affects disease outcome), or are associated with other side effects 
(244). It has been proposed that active immunization with ICD-
based anticancer vaccines (which are associated with robust 
immunogenicity) given in a repetitive manner may achieve this 
goal (Figure 2) (234, 243, 245). Thus, it will be important to test 
whether the long-term administration of ICD-based anticancer 
vaccines can sustain the effector function of TAA-specific T cells 
bearing low-affinity TCRs, hence, ensuring lifelong disease-free 
survival. Of note, in the case of hematological malignancies, this 
issue could be overcome upon the adoptive transfer of CTLs 
expressing chimeric antigen receptors (CARs) (1). However, 
whether CAR-expressing CTLs generate protective immunologi-
cal memory in the absence of considerable side effects remains 
to be determined. Moreover, the use of this therapeutic strategy 
against solid malignancies is relatively challenging owing to lack 
of well-defined “unique” TAAs (1, 246).
ConClUsion
The model of ICD has been considerably refined since the initial 
identification of a cell death modality manifesting apoptotic fea-
tures but able to induce an adaptive immune response. This model 
strives to integrate several phenomena observed throughout the 
second half of the twentieth century in one therapeutically rel-
evant platform. However, as discussed above, several challenges 
still need to be addressed. First, comprehensive testing should be 
performed in advanced experimental settings like GEMMs or 
orthotopic tumor models. Second, ICD resistance mechanisms 
should be characterized with precision. Third, various issues 
linked to the successful translation of ICD to cancer therapy 
will have to be resolved, including (but not limited to) treatment 
schedules, dosages, and combinatorial strategies. This transla-
tional drive also needs to be coupled with effective strategies for 
the discovery of new and effective ICD inducers. Drug screening 
programs are often complicated by the possibility of false-positive 
(due to bystander presence of DAMPs) (30) or false-negative (due 
to limited number of biomarkers used for screening) hits. This 
issue can only be ironed out by discovering new and common 
regulators of ICD, and integrating them into existing screening 
platforms. Last, but not least, it will be important to identify new 
ICD-related/derived biomarkers that can be used to improve 
current protocols of patient stratification and clinical decision 
making. We are positive that all these objectives are at reach.
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taBlE 1 | a list of prominent damage-associated molecular patterns (DaMPs) associated with cell death pathways or extracellular matrix.
DaMPs localization and 
mode-of-emission
Relevant cell death 
pathway
Receptors Reference
Annexin A1 Surface exposed or actively/
passively released?
Apoptosis FPR-1 receptor (33)
Adenosine triphosphate Actively or passively released ICD, apoptosis/secondary 
necrosis and necrosis
P2Y2 and P2×7 (34–37)
B-cell CLL/lymphoma 2 Passive release Necrosis TLR2 (38)
Biglycan Extracellular matrix – TLR2, TLR4, P2×4, 
and P2×7
(39, 40)
Calreticulin Mostly surface exposed; 
sometimes passively released
ICD CD91 (35, 41–44)
Cardiolipin Surface exposed? Apoptosis ? (45, 46)
Ceramide and sphingosine-1-phosphate Surface exposed Apoptosis ? (47)
Covalent/cross-linked dimer of ribosomal protein S19 Passively released? Apoptosis CD88 (48–51)
Carbamoyl-phosphate synthase 1 ? ? ? (52)
Cyclophilin A Passive release Necrosis CD147 (53)
Cytochrome c Passively released? Secondary necrosis and 
necrosis?
LPG? (54, 55)
Death domain 1α Surface exposed Apoptosis DD1α (56)
Endothelial monocyte-activating polypeptide II Passively released? Apoptosis CXCR3? (50, 57, 58)
F-actin Passive release Necrosis DNGR-1/Clec9a (59)
Fibrinogen Extracellular matrix – TLR4 (40)
Fibronectin extra domain A Extracellular matrix – TLR4? (40)
Fragments of human tyrosyl tRNA synthetase Passively released? Apoptosis ? (50)
Genomic DNA, mRNA, snRNPs Passive release Necrosis TLR3 (3, 60, 61)
GRP78/BiP Passive release Necrosis, apoptosis? ? (31)
H202 ? Apoptosis ? (62)
Heat shock proteins (HSP70, HSP90, HSP60, HSP72,  
and GP96)
Surface exposure, active 
secretion, or passive release
ICD, apoptosis/secondary 
necrosis, necrosis
CD91, TLR2, TLR4, 
SREC-1 and FEEL-1
(63–67)
Heparan sulfate fragments Extracellular matrix – TLR4 (40)
Hepatoma-derived growth factor Passively released Necrosis ? (68)
Histones Passively released Necrosis TLR-9 (69)
High-mobility group box 1 Mostly passively released; 
sometimes actively released
ICD, secondary necrosis 
and necrosis
TLR2, TLR4, RAGE 
and TIM3
(70–73)
High-mobility group nucleosome binding domain 1 Passive release Necrosis TLR4 (74)
Hyaluronan Extracellular matrix – TLR2 and TLR4 (40)
IL-1α Passive release Necrosis IL-1R (75)
IL-33 Passive release Necrosis ST2 (3, 61)
IL-6 Passive release Necrosis IL-6R and GP130 (76)
Lysophosphatidylcholine Passively released? Apoptosis G2A (50, 77)
Mit DNA Passively released Necrosis TLR-9 (78–80)
Monosodium urate or uric acid Passively released Necrosis Purinergic receptors (50, 81)
N-formylated peptides Passively released Necrosis FPR-1 (78, 82–84)
Oxidation-associated molecular patterns (reactive protein 
carbonyls, per-oxidized phospholipids, oxidized low-density 
lipoprotein)
Passively released Necrosis, Secondary 
necrosis
CD36, SR-A, TLR-
2/4, CD14
(85–87)
Peroxiredoxin 1 Actively secreted or passively 
released
Apoptosis, necrosis TLR4 (88)
(Continued)
taBlEs
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taBlE 2 | Danger signaling pathways characterized as traffickers of DaMPs.
DaMPs Role of 
Ros
Role 
of ER 
stress
Role of 
autophagy
Role of 
chaperone-
mediated 
autophagy
Role of 
secretory 
pathway
Caspase 
activity
Role of 
lysosomes
Comments Reference
Secreted 
ATP
+ +/0 +/0 0 +/0 + +/0 Underlying pathway is highly inducer dependent (34, 35, 
111–113)
Released 
HMGB1
0 0 + ? 0 – ? Mostly released passively on account of 
necrosis; only DT-EGF reported to cause active 
secretion so far
(73, 114, 
115)
Secreted 
or surface 
HSP70
? ? ? ? ? + + ABC transporters help in endolysosomal-
secretion; HSP70 has also been reported to be 
secreted in an exosome surface-bound format
(116–122)
Surface 
CRT
+ + −/0 + + +/0 ? LRP1/lipid rafts mediate surface tethering; 
components that positively regulate surface-CRT 
in an inducer-dependent fashion: ERp57, PI3K 
p110α, BAX/BAK, cytosolic ER-Ca2+, BAP31; of 
note, anthracycline-induced pathway of surface 
CRT induction has been found to be conserved 
from yeast to mammals
(34, 35, 
111, 112, 
116, 123, 
124)
Surface 
HSP90
+ + – ? + + ? – (30, 125)
“+” denotes ability to positively regulate trafficking; “−” denotes ability to negatively regulate trafficking; “0” denotes confirmation of no role in regulation of trafficking and “?” denotes 
that the role in regulating the trafficking is unknown; “+/0” denotes positive or no role in regulation of trafficking in an inducer-dependent fashion; “−/0” denotes negative or no role in 
regulation of trafficking in an inducer-dependent fashion.
ATP, adenosine triphosphate; CRT, calreticulin; DT-EGF, epidermal growth factor receptor-targeted diphtheria toxin; ER, endoplasmic reticulum; HMGB1, high-mobility group box 1 
protein; HSP, heat shock protein; LRP1, low-density lipoprotein receptor-related protein 1; ROS, reactive oxygen species.
DaMPs localization and 
mode-of-emission
Relevant cell death 
pathway
Receptors Reference
Phosphatidylserine Actively externalized on the 
surface
Apoptosis TIM-1/-3/-4, BAI1, 
Stabilin-2, MFG-E8, 
C1q
(56, 89–93)
S100/calgranulin protein family members (S100A8, S100A9, 
S100A12/EN-RAGE)
Passively released Necrosis RAGE (50, 94)
Tenascin-C Extracellular matrix – TLR4? (95)
Thrombospondin 1 and its heparin-binding domain Passively released or surface 
associated
Apoptosis αvβ3 integrin (50, 96)
Versican Extracellular matrix – TLR2, TLR6, and 
CD14
(40)
CD, cluster of differentiation; CLEC9A, C-type lectin domain family 9, member A; CPS-1, carbamoyl-phosphate synthase 1, mitochondrial; CXCR3, C-X-C motif receptor 3; FEEL-1/
CLEVER-1, fasciclin EGF-like/common lymphatic endothelial and vascular endothelial receptor-1; FPR-1, formyl peptides receptor-1; G2A, G2 accumulation; HMGB1, high-mobility 
group box 1; HSP, heat shock proteins; ICD, immunogenic cell death; IL, interleukin; LPG, leucine-rich alpha-2-glycoprotein-1; MFG-E8, milk fat globule-egf factor 8 protein; Mit 
DNA, mitochondrial DNA; P2XR, P2X receptor; P2YR, P2Y receptor; RAGE, receptor for advanced glycation endproducts; SREC-1, scavenger receptor class f member 1; TFAM, 
mitochondrial transcription factor A; TIM, transmembrane immunoglobulin and mucin domain; TLR, toll-like receptor(s).
Glossary (5, 19, 97): (1) Necrosis: primary necrosis is a form of cell death that can occur in a regulated or accidental manner, characterized by cellular swelling and rapid breakdown 
of the plasma membrane; (2) Necroptosis: necroptosis is a form of regulated cell death (RCD) manifesting with necrotic morphology and controlled by a signaling cascade involving 
(among other proteins) RIPK1, RIPK3, and MLKL; (3) Apoptosis: apoptosis is a form of RCD largely dependent on caspases activity and morphologically characterized by cell 
shrinkage, membrane blebbing, formation of apoptotic bodies, chromatin condensation, and systematic DNA fragmentation; (4) Secondary Necrosis: Secondary necrosis is a terminal 
process experienced by late-apoptotic cells if they are not cleared by phagocytes in time, and is characterized by general spill-over of apoptotic cellular contents.
“?” Unclear or not determined yet.
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taBlE 3 | a list of prominent single-agent immunogenic cell death (iCD) inducers in cancer and their specific associations with danger signaling and 
other immunostimulatory signaling.
iCD inducers associated iCD-relevant DaMPs other immunostimulatory activities or danger signals and other 
comments on immunomodulatory activity
Reference
DaMP stage of cell death
Anthracyclines 
(epirubicin, 
doxorubicin, idarubicin, 
mitoxantrone), 
oxaliplatin, UVC 
radiation and 
radiotherapy
Surface CRT
Surface HSP70
Secreted ATP
Released HMGB1
Pre-apoptotic
Mid-apoptotic
Early/mid-apoptotic
Post-apoptotic
Activation of Type I IFN response comprising MX-1 centered signature, 
consisting of IFN-α/β and CXCL10; surface exposure of mannose-6-phopshate 
receptor, which enables better interface with CTLs and facilitates GZMB-
mediated cell death; radiotherapy is known to increase expression levels of 
various antigens in number of cancer models as well as induce “abscopal 
effect” in both preclinical and clinical models; overall CALR levels were 
predictive of prolonged OS in radiotherapy-treated lung cancer patients
(26, 42, 
102, 127, 
141–144)
Anti-EGFR 
antibody – 7A7
Surface CRT Pre-apoptotic – (145)
Surface HSP70 Early/mid-apoptotic
Surface HSP90 Early/mid-apoptotic
Bleomycin Surface CRT Mid/post-apoptotic Induces ambivalent immune response, i.e., all valid ICD markers but also 
increased Treg differentiation and, thus, a good candidate for anti-Treg 
combinatorial therapy
(146)
Secreted ATP Mid/post-apoptotic
Released HMGB1 Post-apoptotic
Bortezomib Surface HSP90 Early/mid-apoptotic – (26, 66, 
100, 127)Surface CRT Early/mid-apoptotic
Surface HSP70 Early/mid-apoptotic
Oncolytic Adenovirus Surface CRT ? Immunogenicity of these viruses can be further increased by producing 
transgenic versions producing CD40L or GM-CSF
(147, 148)
Released ATP
Released HMGB1
Clostridium difficile 
toxin B
Surface CRT Early/mid-apoptotic – (149)
Released ATP Post-apoptotic
Released HMGB1 Post-apoptotic
Released HSP70/90 Post-apoptotic
Coxsackievirus B3 
(CVB3)#
Surface CRT Early-apoptotic – (150, 151)
Secreted ATP Early/mid-apoptotic
Released HMGB1 Post-apoptotic
Cyclophosphamide Surface CRT Pre-apoptotic Facilitates an interface between gut microbiota (leaked due to gut perforation) 
and host immune system thereby allowing Th17 cells-dependent anti-tumor 
immune responses; cyclophosphamide’s effects on anti-tumor immunity 
are strongly dose dependent. High doses of this chemotherapeutic can 
be immunosuppressive yet low or metronomic doses facilitate anti-tumor 
immunity through targeted depletion of Tregs/MDSCs. In ICD set-up, a low 
dose (100 mg/kg in mice) of cyclophosphamide was shown to exert anti-tumor 
immunity
(18, 152, 
153)Released HMGB1 Post-apoptotic
High hydrostatic 
pressure
Surface CRT Early/mid-apoptotic – (154–156)
Surface HSP70 Early/mid-apoptotic
Surface HSP90 Early/mid-apoptotic
Secreted ATP Mid/post-apoptotic
Released HMGB1 Mid/post-apoptotic
Hypericin-based PDT Surface CRT Pre-apoptotic High accumulation of OAMPs like protein carbonyls; down-regulates CD47; 
induces up-regulation of various molecules associated with Type I IFN response 
(IRF7, IRF1, OASL, IL18, CXCL2, IL15, IL8) but not IFN-α secretion
(26, 30, 
34, 35, 
112, 116, 
157)
Surface HSP70 Pre-apoptotic
Surface HSP90 Pre-apoptotic
Secreted ATP Pre-apoptotic
Released HMGB1 Post-apoptotic
Released HSP70/90 Post-apoptotic
Released CRT Post-apoptotic
Microwave thermal 
ablation
Surface CRT ? – (158)
Secreted ATP
Released HMGB1
Newcastle disease virus 
(NDV)
Surface CRT Early/mid-necroptotic Increases expression levels of PMEL17 antigen in glioma cells; NDV treatment 
has also been shown to induce “abscopal effect” in a murine melanoma model
(43, 159)
Released HMGB1 Post-necroptotic
Paclitaxel Surface CRT
Released HMGB1
Early/mid-apoptotic
Post-apoptotic
Overall CALR levels were predictive of prolonged OS or PFS in paclitaxel-
treated ovarian cancer patients thereby establishing clinical validity of ICD in 
paclitaxel treatment set-up; paclitaxel has also been reported to enhance overall 
antigen levels
(42, 144, 
160)
(Continued)
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iCD inducers associated iCD-relevant DaMPs other immunostimulatory activities or danger signals and other 
comments on immunomodulatory activity
Reference
DaMP stage of cell death
Patupilone Surface CRT Early/mid-apoptotic – (128)
Photofrin-based PDT Surface CRT Early/mid-apoptotic The only anticancer modality for which a comparison between DAMPs  
induced by in vitro versus in vivo treatment was carried out – however, none  
of ICD-related DAMPs were tested
(47, 
161–164)Surface HSP70/60 Early/mid-apoptotic
Released HMGB1 Post-apoptotic
Surface ceramide Early/mid-apoptotic
Surface S1P Early/mid-apoptotic
PtII N-heterocyclic 
carbene complex
Surface CRT Pre-apoptotic – (140)
Released ATP Post-apoptotic
Released HMGB1 Post-apoptotic
RIG-I-like helicases 
(RLH) ligand
Surface CRT Early-apoptotic Induces Type I IFN response (165)
Released HMGB1 Post-apoptotic
Released HSP70 Post-apoptotic
Septacidin Surface CRT Pre-apoptotic – (139)
Secreted ATP Early/mid-apoptotic
Released HMGB1 Post-apoptotic
Shikonin Surface CRT Early/mid-apoptotic Also, causes surface exposure of GRP78 a prominent inducer of pro-
tumorigenic effects; enhances overall cancer antigen levels
(160)
Surface HSP70 Early/mid-apoptotic
Vorinostat Surface CRT Early/mid-apoptotic – (166)
Secreted ATP Post-apoptotic
Released HMGB1 Post-apoptotic
Wogonin Surface CRT Early-apoptotic Surface-Annexin A1 is also induced by wogonin. In an ICD set-up, the role of 
Annexin A1 is not clear since it is a noted anti-inflammatory factor
(167)
Released ATP Post-apoptotic
Released HMGB1 Post-apoptotic
CRT or CALR, calreticulin; CTLs, cytotoxic T lymphocytes; DAMPs, damage-associated molecular patterns; EGFR, epidermal growth factor receptor; GZMB, granzyme B; HMGB1, 
high-mobility group box-1 protein; HSP, heat shock protein; ICD, immunogenic cell death; IFN, interferon; MDSC, myeloid-derived suppressor cells; OAMPs, oxidation-associated 
molecular patterns; OS, overall survival; PFS, progression-free survival.
Important note: It is worth noting that recently various promising candidate therapies have emerged that induce in vitro DAMPs relevant for ICD, e.g., Rose Bengal-based PDT (168), 
Docosahexaenoic acid (169), and Capsaicin (170, 171). Such agents may emerge as potent inducers of ICD in future, however, in order to establish them as inducers of ICD-like 
immunogenicity, it is imperative to confirm their (i.e., cancer cells treated with these agents) ability to stimulate T cells (in vitro or in vivo) and/or induce anti-cancer vaccination effect, 
in vivo, as per the consensus guidelines (104).
Glossary: In the current setting, it is crucial to differentiate between the meanings of the words, “immunogenic” and “immunogenicity” as they are not supposed to have inter-
changeable meanings. Immunogenic, derives from the word immunogen, which refers to any substance that can elicit an immune response; this includes, whole cells or organisms 
(eukaryotic or prokaryotic), specific cellular entities or specific proteins (e.g., antigens) (172). On the other hand, immunogenicity is a much more specific terms that is closer to 
antigenicity in operational sense, since it refers to the ability of a specific entity (e.g., an antigen or an epitope) to be recognized by the immune system through binding interactions 
with T or B cells, which may or may not result in an overt immunological response (4, 11).
“?” Unclear or not determined yet.
“#” Unconfirmed anti-tumour immune responses in adaptive immune system-competent.
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taBlE 4 | Classification of iCD inducers into type i and type ii based on their ER or non-ER-targeting modus operandi.
iCD inducer site of Cell-death inducing effects site of danger 
signaling induction
Reference
type i inducers – agents that induce icd through a “collateral” er stress effect
Anthracyclines (epirubicin, doxorubicin, idarubicin, 
mitoxantrone), oxaliplatin, UVC radiation and radiotherapy
Nucleus (DNA or the DNA replication machinery 
proteins)
ER, autophagy, 
pannexin channels, 
lysosomes
(36, 41, 70, 111, 130, 173, 
174)
Anti-EGFR antibody – 7A7 Cell surface (epidermal growth factor receptor or 
EGFR)
ER (145)
Bleomycin Nucleus (causes DNA strand-breaks) ER? (146)
Bortezomib Cytosol (26S proteasome or ERAD machinery; 
CIP2A/cancerous inhibitor of protein phosphatase 
2A)
ER (100, 175, 176)
Clostridium difficile toxin B Cytoskeleton (causes cytoskeletal disruption by 
targeting RhoA, CDC42 and Rac1)
ER (149, 177)
Cyclophosphamide Nucleus (DNA) ER (152)
High hydrostatic pressure Broad disrupting/denaturing effects on 
membranes, and proteins
ER (mitochondria?) (154, 178)
Microwave thermal ablation Hyperthermic ablation of cellular components ER? (158)
Paclitaxel, patupilone Cytoskeleton (target microtubules thereby 
disrupting cytoskeletal functions)
ER (42, 104, 179)
Photofrin-based PDT Cellular membranes (ROS-based damage of 
membranes)
ER? (180, 181)
RIG-I-like helicases (RLH) ligand Cytosol (targets RIG-I-like helicases) ER? (165)
Septacidin ? ER (139)
Shikonin Cytosol (tumor-specific pyruvate kinase-M2 
protein)
ER (160, 182)
Vorinostat Nucleus/Cytosol (targets histone deacetylase) ER? (166)
Wogonin Mitochondria (generates mitochondria-derived 
ROS)
ER (167, 183)
type ii inducers – agents that induce icd through a “focused” er stress effect
Hypericin-based PDT ER (ROS-based damage at the ER membrane) ER (35, 63, 116, 181, 184, 185)
Oncolytic adenovirus ER (ER membranes and lumen) ER (104, 147)
Oncolytic coxsackievirus B3 (CVB3) ER (ER membranes and lumen) ER (150, 186)
Oncolytic Newcastle disease virus (NDV) ER (ER membranes and lumen) ER (43, 159, 187)
PtII N-heterocyclic carbene complex Predominantly targets ER (generates ER-directed 
ROS)
ER (140)
EGFR, epidermal growth factor receptor; ER, endoplasmic reticulum; ICD, immunogenic cell death; PDT, photodynamic therapy; ROS, reactive oxygen species.
“?” Unclear or not determined yet.
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taBlE 5 | a list of molecular and immunological components crucial for regulation of iCD.
Molecular or 
immunological 
components
acting on the 
level of?
Role in regulating iCD or iCD-related determinants for 
various therapies/inducers
Confirmed by which experimental 
intervention?
Reference
Positive regulation negative 
regulation
no role in 
regulation
Actin cytoskeleton Cancer cells Anthracyclines, hypericin-PDT – – Pharmacological inhibitors of actin 
polymerization
(35, 123)
ATG5, ATG7, or 
BECN1
Cancer cells Anthracyclines, oxaliplatin Hypericin-PDT Newcastle 
disease 
virotherapy
ATG5, ATG7 or BECN1 si/shRNA, 
ATG5 KO MEFs, or transgenic mice 
model of spontaneous melanoma with 
Atg7−/− phenotype or pharmacological 
inhibitors of macroautophagy
(34, 43, 112)
BAX/BAK Cancer cells Anthracyclines, hypericin-PDT – – BAX/BAK KO MEFs or Bax/Bak si/
shRNA
(35, 123)
Calreticulin Cancer cells Anthracyclines, radiotherapy, 
oxaliplatin, hypericin-PDT
– – CRT si/shRNA (35, 41, 116, 
123)
Caspase 1 Host immune 
system
Anthracyclines and/or oxaliplatin – – Casp1−/− mice (36)
Caspase-8 Cancer cells Anthracyclines – Hypericin-
PDT
Caspase-8 si/shRNA or HeLa cancer 
cells expressing CrmA (a caspase-8 
inhibitory protein)
(35, 123)
CD4+/CD8+ T cells Host immune 
system
Anthracyclines and/or oxaliplatin, 
hypericin-PDT, high hydrostatic 
pressure, bortezomib, vorinostat, 
photofrin-PDT, Newcastle disease 
virotherapy, cyclophosphamide
– – Antibody-based depletion; Ex vivo 
co-culture experiments
(34, 43, 100, 
102, 152, 161, 
162, 166, 191)
CXCL10 Host immune 
system
Anthracyclines and/or oxaliplatin – – Recombinant protein (102, 141)
CXCR3 Host immune 
system
Anthracyclines and/or oxaliplatin – – Cxcr3−/− mice or antibody-based 
blockade
(141)
eIF2α-P Cancer cells Anthracyclines – Hypericin-
PDT
MEFs expressing non-phosphorylable 
version of eIF2α-P, salubrinal or 
pharmacological inhibitors of GADD34
(35, 123)
ER-Ca2+ Cancer cells Anthracyclines – Hypericin-
PDT
BAPTA, a Ca2+ chelator or Reticulon-1C 
overexpression;
(35)
ERp57 Cancer cells Anthracyclines – Hypericin-
PDT
ERp57 si/shRNA or ERp57 KO MEFs (35, 116)
ER-to-Golgi 
transport
Cancer cells Anthracyclines, hypericin-PDT – – Brefeldin A, a secretory pathway 
inhibitor
(35, 123)
HMGB1 Cancer cells Anthracyclines – – HMGB1 si/shRNA (70)
HSP90 Cancer cells Bortezomib – – Pharmacological HSP90 inhibitors (66, 67, 100)
HSP70 Cancer cells Shikonin – – Antibody-mediated protein depletion (192)
IFN-α/β or 
IFN-α-receptor
Cancer cells Anthracyclines, cyclophosphamide, 
and/or oxaliplatin
– – Antibody-based blockade or 
recombinant proteins (wherever 
applicable)
(141, 152)
IFN-γ and 
IFN-γ-receptor
Host immune 
system
Anthracyclines and/or oxaliplatin – – Ifng−/− or Ifngr1−/− mice (70, 102)
IL17A or 
IL17A-receptor
Host immune 
system
Anthracyclines and/or oxaliplatin – – Il17a−/− or Il17ra−/− mice (36, 193)
IL1-receptor Host immune 
system
Anthracyclines and/or oxaliplatin – – Il1r1−/− mice (36)
IL-1β Host immune 
system
Anthracyclines and/or oxaliplatin – – Antibody-based blockade (36)
Lipid rafts Cancer cells Mitoxantrone – Hypericin-
PDT
MBC, a cholesterol-chelator that 
disrupts lipid rafts
(35)
(Continued)
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Molecular or 
immunological 
components
acting on the 
level of?
Role in regulating iCD or iCD-related determinants for 
various therapies/inducers
Confirmed by which experimental 
intervention?
Reference
Positive regulation negative 
regulation
no role in 
regulation
LRP1 Cancer cells Mitoxantrone, hypericin-PDT – – LRP1 shRNA, LRP1 KO MEFs, 
LRP1 KO CHO cells and LRP1 
overexpression in CHO cells
(35)
LY96 and MyD88 
(TLR-adaptors)
Host immune 
system
Anthracyclines and/or oxaliplatin – – Ly96−/− or Myd88−/− mice (102)
NLRP3 Host immune 
system
Anthracyclines and/or oxaliplatin – – Nlrp3−/− mice (36)
P2 × 7 receptor Host immune 
system
Anthracyclines and/or oxaliplatin – – P2rx7−/− mice (36)
Perforin Host immune 
system
Anthracyclines and/or oxaliplatin – – Prf1−/− mice (36, 70, 102)
PERK Cancer cells Anthracyclines, hypericin-PDT, 
wogonin
– – PERK si/shRNA, PERK KO MEFs (35, 123, 167)
PI3K p110α Cancer cells Anthracyclines, hypericin-PDT, 
wogonin
– – PI3K p110α shRNA or wortmannin, a 
pharmacological inhibitor
(35, 167)
Rag2 Host immune 
system
Anthracyclines and/or oxaliplatin, 
vorinostat, cyclophosphamide, 
photofrin-PDT, Newcastle disease 
virotherapy
– – Rag2−/− mice (43, 70, 102, 
152, 161, 162, 
166)
STAT3 Cancer cells Anthracyclines and/or oxaliplatin – – Stat3−/− cancer cells (194)
TLR3 Cancer cells Anthracyclines and/or oxaliplatin – – TLR3 si/shRNA or Tlr3−/− cancer cells (141)
TLR4 Host immune 
system
Anthracyclines and/or oxaliplatin – – Tlr4−/− mice (70, 102)
TNF or TNF-receptor Host immune 
system
Anthracyclines and/or oxaliplatin – – Tnf−/− or Tnfr1−/− mice (102)
LAMP2A Cancer cells? Mitoxantrone and hypericin-PDT – – LAMP2A KO MEFs (112)
ATG, autophagy-related protein; BECN1, beclin-1; CD, cluster of differentiation; CRT, calreticulin; CXCL, C-X-C ligand; CXCR, C-X-C motif receptor; eIF2, eukaryotic initiation 
factor 2; ER, endoplasmic reticulum; ERp57, endoplasmic reticulum protein 57; HMGB1, high-mobility group box 1; HSP, heat shock protein; Hyp-PDT, hypericin-based 
photodynamic therapy; ICD, immunogenic cell death; IFN, interferon; IL, interleukin; KO MEFs, knock-out murine embryonic fibroblasts; LAMP, lysosome-associated membrane 
glycoprotein; LRP1, low-density lipoprotein receptor-related protein 1; MBC, methyl-β-cyclodextrin; NLRP3, NOD-like receptor family, pyrin domain containing 3; PERK, protein 
kinase RNA-like endoplasmic reticulum kinase; PI3K, phosphoinositide 3-kinase; PRF, perforin; TLR, toll-like receptor; TNF, tumor necrosis factor.
taBlE 5 | Continued
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taBlE 6 | a list of prominent preclinical mice or rat models used for analysis of iCD.
iCD inducer Mice tumor models utilized for positive iCD characterization or iCD “restoration/rescue” analysis
Heterotopic subcutaneous mice or rat models orthotopic mice 
models
spontaneous tumor 
mice models
Carcinogen-induced 
tumor models
Anthracyclines CT26 cells in BALB/c mice – prophylactic immunization model (41, 70, 
111, 123, 197) and curative tumor model (41, 70, 111, 197); MCA205 
cells in C57BL/6 mice – prophylactic immunization and curative tumor 
model (36, 70, 111, 130); MCA-2/-4 cells in C57BL/6 mice – curative 
tumor model (36); D122 cells in C57BL/6 mice – prophylactic 
immunization model (145); AY27 cells in Fischer 344 rats – prophylactic 
immunization model (42)
– MMTV-NeuT 
breast cancer mice 
model – curative set-up 
(198); BrafCa/+;  
Ptenfl/fl-melanoma mice 
model – curative set-up 
(199)
–
Anti-EGFR  
antibody (7A7)
D122 cells in C57BL/6 mice – curative tumor model and prophylactic 
immunization model (145)
– – –
Bleomycin CT26 cells in BALB/c mice – curative tumor model (146) – – –
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iCD inducer Mice tumor models utilized for positive iCD characterization or iCD “restoration/rescue” analysis
Heterotopic subcutaneous mice or rat models orthotopic mice 
models
spontaneous tumor 
mice models
Carcinogen-induced 
tumor models
Bortezomib 67NR cells in BALB/c mice – prophylactic immunization model with use 
of stimulated DCs (200); B16 cells in C57BL/6 mice – curative tumor 
model, combination treatment with AdVMART1/DC and bortezomib is 
significantly better than bortezomib alone (201); HM-1 cells in C57BL/6 x 
C3/He F1 origin mice – prophylactic immunization model (202)
– – –
CD40L-encoding 
Oncolytic 
Adenovirus
MB49 cells in C57BL/6 mice – curative tumor model (147) – – –
Clostridium difficile 
toxin B
CT26 cells in BALB/c mice – prophylactic immunization model (149) – – –
Coxsackievirus B3 A549 and EBC-1 cells in nude BALB/c mice – curative tumor  
model (150)
– – –
Cyclophosphamide EG7 cells in C57BL/6 mice (152); AB1-HA cells in BALB/c 
mice – curative tumor model followed by resistance to challenge with live 
cells (203)
– – –
Hypericin-based 
PDT
CT26 cells in BALB/c mice – prophylactic immunization model 
(35); – curative tumor model (184); AY27 cells in Fischer 344 
rats – prophylactic immunization model (42); B78 cells in C57BL/6 
mice – prophylactic immunization model (30)
– – –
Microwave thermal 
ablation
K7M2 cells in BALB/c mice or UMR106 cells in SD rats – prophylactic 
immunization model (158) 
– – –
Newcastle disease 
virus (NDV)
B16 cells in C57BL/6 mice – curative tumor model (159) GL261 cells 
in C57BL/6 
mice – curative 
tumor model (43)
– –
Oxaliplatin CT26 cells in BALB/c mice – prophylactic immunization model (123, 
197); – curative tumor model (197); EL4 cells in C57BL/6 mice – curative 
tumor model (36); EG7 cells in C57BL/6 mice – curative tumor model 
(36); EG7 cells in C3H mice – prophylactic immunization model (70)
– – –
Photofrin-based 
PDT
EMT6 cells in BALB/c mice – curative tumor model (161); SCCVII cells in 
C3H/HeN mice – curative tumor model (162, 163)
– – –
Radiotherapy CT26 cells in BALB/c – prophylactic immunization model (204); 410.4 
cells in BALB/c mice – prophylactic immunization model (205); EG7 
cells in C57BL/6 mice and SCC VII cells in C3H mice – prophylactic 
immunization model (206); B16F10 cells in C57BL/6 mice – prophylactic 
immunization model with the use of irradiated cancer cells, as well as 
DCs stimulated with irradiated cancer cells (207)
– – –
RIG-I-like helicases 
(RLH) ligand
Panc02 cells in C57BL/6 mice – prophylactic immunization and curative 
tumor model (165)
– – –
Septacidin MCA205 cells in BALB/c mice – prophylactic set-up (139); – – –
Shikonin B16 cells in C57BL/6 mice – prophylactic immunization model (160); 
P388 cells in KMF mice – curative tumor model (208)
4T1 cells in BALB/c 
mice – curative 
tumor model (192);
– –
UVC irradiation CT26 cells in BALB/c mice – prophylactic immunization model (204); 
EG7 cells in C57BL/6 mice – curative tumor model (152)
– – –
Vorinostat MC38 or Eμ-myc 4242/299 lymphoma in C57BL/6 mice – curative 
tumor set-up (166)
– – –
High hydrostatic 
pressure
No mice or rat based preclinical data available to support their ICD-functions
PtII N-heterocyclic 
carbene complex
DC, dendritic cell; ICD, immunogenic cell death; PDT, photodynamic therapy.
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taBlE 7 | Existence of intrinsic or naturally occurring resistance to iCD in experimental cancer models.
iCD 
inducer(s)
Experimental set-up 
where resistance 
was observed
Reason behind Resistance Rescued by? Clinical applicability verified? Reference
In vivo preclinical setting (cancer cell or host immune system-level resistance)
Anthracyclines 
or 
anthracycline 
plus oxaliplatin
C3H mice with 
naturally occurring tlr4 
mutation
Host immune system-level resistance: defective 
TLR4 in C3H mice causes failure of HMGB1-
mediated immunity thereby leading to resistance 
to anti-cancer vaccination effect associated with 
anthracyclines treatment
Adoptive transfer 
of TLR4-
expressing DCs 
loaded with dying 
tumor cells
Yes; breast cancer, colon cancer, and 
lung cancer patients carrying TLR4 
gene mutation that ablates its ability 
to bind its ligands is associated with 
worse prognosis post-treatment
(215)
Doxorubicin AT-3 or 4T1.2 breast 
cancer cells in 
C57BL/6 or BALB/c 
mice, respectively
Cancer cell-level resistance: CD73 overexpression 
confers chemo-resistance to doxorubicin by 
suppressing anti-tumor immunity through A2A 
adenosine receptors
Blockade of CD73 Yes; in triple-negative breast cancer 
patients, high CD73 in anthracycline-
treatment set-up associated with 
lower rate of complete responses
(216)
Mitoxantrone 
and 
Hypericin-PDT
AY27 rat bladder 
cancer cells in Fischer 
344 rats
Cancer cell-level resistance: low endogenous CRT 
levels, resulted in severely reduced surface-CRT 
upon treatment with mitoxantrone or Hyp-PDT; 
this in turn compromised immunogenic phagocytic 
clearance and anti-cancer vaccination effect
Exogenous 
addition of 
recombinant CRT
Yes; high tumoral CALR levels 
correlated with high expression of 
phagocytosis-associated genes 
and predicted for prolonged survival 
after RT or PTX treatment of lung or 
ovarian cancer patients respectively
(42)
Oxaliplatin Autochthonous 
transgenic 
adenocarcinoma of 
the mouse prostate 
(TRAMP) model of 
metastatic prostate 
cancer
Host immune system-level resistance: 
immunosuppressive B cells expressing IgA, IL10 
and PD-L1 cause resistance to anti-tumorigenic 
effects of oxaliplatin
Genetic or 
pharmacological 
depletion of B cells
Not directly, but possible validity is 
supported by human patient data 
showing that IL-10 expressing IgA+ 
cells are abundant in therapy-
resistant prostate cancer and are 
negative prognostic indicators
(217)
In vitro preclinical setting (cancer cell-level resistance)
Anthracycline SH-SY5Y 
neuroblastoma cell 
line
Anthracycline treatment of these cells failed to 
induce surface-CRT due to reduced capacity to 
efflux ER-Ca2+ into cytosol
Overexpression of 
reticulon-1C
– (132)
Doxorubicin HT29-dx and HT29 
iNOS-cells (human 
colon cancer cells)
Doxorubicin failed to induce NO synthesis, which 
resulted in reduced toxicity, reduced surface-CRT 
and subsequently compromised immunogenic 
phagocytic clearance and DC stimulation
Addition of sodium 
nitroprusside or a 
NO donor
– (218)
Doxorubicin MDR+ human cancer 
cells (HT29-dx, A549-
dx and MCF-7-dx)
Increased MDR levels caused increased 
P-glycoprotein expression which caused 
resistance to doxorubicin-induced ICD by affecting 
immunogenic phagocytic removal
Addition of 
zoledronic acid
Not directly (219)
CD, cluster of differentiation; CRT or CALR, calreticulin; DC, dendritic cells; ER, endoplasmic reticulum; HMGB1, high-mobility group box-1 protein; HSP, heat shock protein; Hyp-
PDT, hypericin-photodynamic therapy; ICD, immunogenic cell death; IL, interleukin; MDR, multiple drug-resistance; NO, nitric oxide; NOS, nitric oxide synthase; PD-L1, programed 
cell death protein ligand 1; PTX, paclitaxel; RT, radiotherapy; TLR, toll-like receptor.
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taBlE 8 | a list of clinical observations supporting the existence of iCD in cancer patients.
iCD inducer standard-of-care therapy or regularly applied 
palliative therapy in clinic?
iCD-related characteristics regulating clinical patient prognosis 
or treatment-responsiveness
Anthracyclines Yes P2RX7 loss-of-function mutation that compromises ICD also 
negatively affects MFS in breast cancer patients treated with 
adjuvant anthracyclines (36); breast cancer patients possessing a 
wild-type TLR4 benefited more from the anthracyclines than those 
who possessed a mutated TLR4 that compromises ICD (70); an 
MX1-centered Type I IFN signature in anthracycline-treated breast 
cancer patients predicts for improved disease outcome (141); 
combined positivity for cytoplasmic LC3B+ puncta and nuclear 
HMGB1 is a positive predictor of improved survival following adjuvant 
anthracycline-based chemotherapy (225)
High hydrostatic pressure No; but HHP-based anticancer DC vaccines  
are currently being applied in clinical trials against 
prostate cancer and ovarian cancer (155)
No data are available
Hypericin-based PDT No; but few clinical trials have been carried out for 
non-melanoma skin cancer (226), cutaneous T-cell 
lymphoma (227), mesothelioma (228), and basal or 
squamous cell carcinoma (229)
No data are available
Oncolytic adenoviruses No; but oncolytic adenoviruses are currently being 
applied in various clinical trials in cancer patients
Serum HMGB1 levels and the temporal change in their levels during 
treatment was identified as a prognostic and predictive biomarker in 
cancer patients (230)
Oxaliplatin Yes Similar to anthracyclines, cancer patients possessing wild-type TLR4 
exhibited prolonged PFS and OS in comparison to patients bearing 
the loss-of-function allele of TLR4 (197)
Paclitaxel Yes High tumoral CALR levels in paclitaxel-treated ovarian cancer patients 
associated with prolonged OS/PFS as well as increased expression 
levels of various phagocytosis-associated genes (42)
Photofrin-based PDT Yes; FDA-approved for application in  
esophageal and lung cancer (231)
No data available
Radiotherapy Yes In patients of eosophageal squamous cell carcinoma (ESCC) receiving 
chemo-radiotherapy significant increase in serum HMGB1-levels and 
increased intra-tumoral staining of HMGB1 correlated with better 
patient survival (232); high tumoral CALR levels in radiotherapy-
treated lung cancer patients associated with prolonged OS as well 
as increased expression levels of various phagocytosis-associated 
genes (42)
Shikonin No; but shikonin is currently being applied in 
an observational clinical study of breast cancer 
patients (NCT01287468)
No data are available
UVC irradiation No; but UV treatment is sometimes applied for 
the preparation of clinical cell-based anticancer 
vaccines (233)
No data are available
Bortezomib, Anti-EGFR antibody 
(7A7), bleomycin, cyclophosphamide, 
microwave thermal ablation, vorinostat
Yes No data are available
Coxsackievirus B3; Clostridium difficile 
toxin B; Microwave thermal ablation; 
Newcastle disease virus (NDV); RIG-I-
like helicases (RLH) ligand; Septacidin; 
PtII N-heterocyclic carbene complex; 
Patupilone
No No data are available
CRT or CALR, calreticulin; HMGB1, high-mobility group box-1 protein; Hyp-PDT, hypericin-photodynamic therapy; ICD, immunogenic cell death; IFN, interferon; OS, overall survival; 
PFS, progression-free survival; TLR, toll-like receptor.
